Kayoko Nakamura
Shinshu University
Cell therapyPhenotypeCellEphrinReceptorKinaseChemistryElectroporationApoptosisIn vivoNeuroblastomaImmunotherapyCD80TrametinibRhabdomyosarcomaMEK inhibitorStem cellMalignant transformationChimeric antigen receptorCancer researchMonoclonal antibodyMAPK/ERK pathwayCell growthAntigen-presenting cellBiologyCell biology
Publications 3
#1Akimasa Tomida (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Tomoko Iehara (Kyoto Prefectural University of Medicine)H-Index: 21
view all 8 authors...
Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. However, the effectiveness of immunotherapy using these cells is limited, and requires improvement. A combinatorial therapy with CAR-T cells and molecular targeted drugs could be a promising strategy to enhance the antitumor efficacy of CAR T-cell immunotherapy. Here, we generated GD2-CAR-T cells vi...
#1Kayoko Nakamura (Shinshu University)
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 9 authors...
Abstract The quality of chimeric antigen receptor (CAR)-T cell products, including the expression of memory and exhaustion markers, has been shown to influence their long-term functionality. The manufacturing process of CAR-T cells should be optimized to prevent early T cell exhaustion during expansion. Activation of T cells by monoclonal antibodies is a critical step for T cell expansion, which may sometimes induce excess stimulation and exhaustion of T cell. Given that piggyBac transposon (PB)...
1 CitationsSource
#1Hiroshi Kubo (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 14
Last. Hajime Hosoi (Kyoto Prefectural University of Medicine)H-Index: 33
view all 9 authors...
Abstract Ephrin type-B receptor 4 (EPHB4), expressed in tumors including rhabdomyosarcoma, is a suitable target for chimeric antigen receptor (CAR)-T cells. Ligand independent activation of EPHB4 causes cell proliferation and malignant transformation in rhabdomyosarcoma, whereas ligand-dependent stimulation of EPHB4 induces apoptosis in rhabdomyosarcoma. Therefore, we hypothesized that ligand-based EPHB4-specific CAR-T cells may kill rhabdomyosarcoma cells without stimulating downstream cell pro...
2 CitationsSource